SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMYLIN PHARM.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Collins who wrote (14)10/31/1996 6:37:00 PM
From: cal buzzell   of 52
 
I find it very odd that the senior management are buying the stock in the secondary, $900,000 worth. Normally, senior management sell a portion of their stock in a secondary. Also, it is unusual that, due to a milestone payment due, J&J and AMLN senior management were allowed to "peek" into the double blind Phase III study. Now, the parties that "peeked" are buying more stock. hmmmmm.
By the way, the secondary was just priced at $10.

Cal
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News